Delcath Systems to Host First Quarter 2022 Results

Rhea-AI Summary

Delcath Systems, a leader in interventional oncology, announced a conference call to discuss its Q1 2022 financial results. The event is scheduled for May 10, 2022, at 8:30 AM ET. Participants can join by dialing in or via webcast. Delcath’s proprietary PHP system delivers high-dose chemotherapy specifically for liver cancers, including metastatic ocular melanoma, under the brand names HEPZATO in the U.S. and CHEMOSAT in Europe. This innovative approach minimizes systemic exposure while targeting cancer effectively, highlighting the company's commitment to advancing cancer treatment.

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 10, 2022, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2022.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Event Date: Tuesday, May 10, 2022
Time: 8:30 AM Eastern Time
Participant Numbers: Toll Free: 877-545-0523; Participant Access Code: 633971
International: 973-528-0016 Participant Access Code: 633971
Webcast: https://www.webcaster4.com/Webcast/Page/2475/45401

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, for the treatment of metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

When is the Delcath Systems conference call for Q1 2022 results?

The conference call is scheduled for May 10, 2022, at 8:30 AM Eastern Time.

How can I participate in Delcath Systems' upcoming conference call?

You can participate by dialing 877-545-0523 (toll-free) or 973-528-0016 (international) with access code 633971, or by joining via the webcast.

What is Delcath Systems’ PHP system used for?

The PHP system is designed to deliver high-dose chemotherapy for primary and metastatic liver cancers, specifically for treating metastatic ocular melanoma.

What are the trade names for the PHP system in the U.S. and Europe?

In the U.S., it's known as HEPZATO, while in Europe, it's marketed as CHEMOSAT.

What date does the Delcath Systems Q1 2022 results call take place?

The call takes place on May 10, 2022.